Program
AGN 194204
Also written as “IRX4204”, “NRX 194204” and “NRX194204”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Psoriasis · Prostatic Neoplasms · Parkinson Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Io Therapeutics | 40 open or running | phase 2since Nov 13, 2011 | Nov 13, 2011 | none ahead |
| NuRx Pharmaceuticals | 10 open or running | phase 2since Aug 20, 2009 | Aug 20, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2009First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to NuRx PharmaceuticalsNuRx Pharmaceuticals · NCT00964132 · 48 enrolled · United States
- Nov 13, 2011Io Therapeutics's first study: phase 2 study in Castration Resistant Prostate CancerNew to Io TherapeuticsIo Therapeutics · NCT01540071 · 38 enrolled · United States
- Aug 7, 2014Phase 1 study in Parkinson DiseaseIo Therapeutics · NCT02438215 · 15 enrolled · United States
- Dec 7, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungIo Therapeutics · NCT02991651 · 12 enrolled · United States
- Dec 4, 2024Phase 2 study in PsoriasisIo Therapeutics · NCT06723171 · 20 enrolled · United States
TargetBeta
“Retinoid X receptor agonist”ChEMBL 37, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06723171Psoriasis · United States | 2 | Suspended | Io Therapeutics | Dec 2027 | 20 |
| NCT02991651Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | Io Therapeutics | May 9, 2025 | 12 |
| NCT02438215Parkinson Disease · United States | 1 | Completed | Io Therapeutics | May 2015 | 15 |
| NCT01540071Castration Resistant Prostate Cancer · United States | 2 | Completed | Io Therapeutics | Dec 2015 | 38 |
| NCT00964132Carcinoma, Non-Small-Cell Lung · United States | 2 | UNKNOWN | NuRx Pharmaceuticals | Mar 2010 | 48 |
How it is read
Names in the registry
- “IRX4204”, 3 entries
- “NRX 194204”, 1 entry
- “NRX194204”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Psoriasis, 1 study
- Prostatic Neoplasms, 1 study
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.